<DOC>
	<DOCNO>NCT01978366</DOCNO>
	<brief_summary>This study design provide 6-months continuous dose study medication , call HT-100 , participant successfully complete predecessor study ( HALO-DMD-01 ) . The main purpose study ass chronic safety , tolerability , pharmacodynamic activity ( test drug 's effect DMD ) population pharmacokinetics ( measure much drug bloodstream ) participant broad spectrum Duchenne muscular dystrophy ( DMD ) .</brief_summary>
	<brief_title>Open Label Extension Study HT-100 Patients With DMD</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Halofuginone</mesh_term>
	<criteria>Completed single ascend dose ( SAD ) multiple ascend dose ( MAD ) phase predecessor study HALODMD01 Maintained corticosteroid therapy predecessor study HALODMD01 Ability provide write informed consent Ambulatory nonambulatory Recent , substantial change use cardiac medication medication affect muscle function Clinically significant major disease , relate DMD Significantly compromise cardiorespiratory function History severe allergic anaphylactic reaction Prior treatment another investigational product past 6 month Inability undergo magnetic resonance imaging ( MRI ) Current drug alcohol abuse prior treatment abuse</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>halofuginone hydrobromide</keyword>
	<keyword>anti-fibrotic</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>muscle regeneration</keyword>
	<keyword>protein synthesis inhibitor</keyword>
</DOC>